TapImmune Inc. (TPIV)

3.16
NASDAQ : Consumer Services
Prev Close 2.97
Day Low/High 2.99 / 3.25
52 Wk Low/High 2.60 / 5.35
Avg Volume 49.70K
Exchange NASDAQ
Shares Outstanding 10.54M
Market Cap 32.35M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

TapImmune To Provide Third Quarter 2017 Business Update Conference Call And Webcast

TapImmune To Provide Third Quarter 2017 Business Update Conference Call And Webcast

Company to Provide Corporate and Clinical Overview on Wednesday, November 15, 2017, at 4:30p.m. ET

TapImmune Provides Second Quarter 2017 Corporate And Clinical Update

TapImmune Provides Second Quarter 2017 Corporate And Clinical Update

Conference Call and Live Audio Webcast Scheduled for Today, August 31, 2017 at 4:30 p.m. ET

TapImmune To Provide Second Quarter 2017 Business Update Conference Call And Webcast

TapImmune To Provide Second Quarter 2017 Business Update Conference Call And Webcast

Company to Provide Corporate and Clinical Overview on Thursday, August 31, 2017, 4:30pm ET

TapImmune Amends Phase 2 Clinical Trial To Focus On Larger Population Of Women With Platinum-Sensitive Ovarian Cancer With Greatest Unmet Need For New Treatments

TapImmune Amends Phase 2 Clinical Trial To Focus On Larger Population Of Women With Platinum-Sensitive Ovarian Cancer With Greatest Unmet Need For New Treatments

Novel T Cell Vaccine TPIV 200 Benefits from FDA Fast Track and Orphan Drug Designation

TapImmune Provides First Quarter 2017 Corporate And Clinical Update

Conference Call and Live Audio Webcast Scheduled for Today at 4:30 pm ET

TapImmune To Provide First Quarter 2017 Business Update Conference Call And Webcast

Company to Provide Corporate and Clinical Overview on Wednesday, May 31, 2017, 4:30pm ET

TapImmune Provides Update On PolyStart™ Vaccine Platform Applicable To Cancer And Infectious Disease

TapImmune Provides Update On PolyStart™ Vaccine Platform Applicable To Cancer And Infectious Disease

TapImmune, Inc. (OTCBB:TPIV), provides an update on the status of its PolyStart TM vaccine technology platform in light of recent global concerns regarding pandemic infections and emerging viral threats such as Ebola...

TapImmune CEO Provides Update On Corporate Activity And Progression Of Clinical Programs

TapImmune CEO Provides Update On Corporate Activity And Progression Of Clinical Programs

TapImmune is a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious disease.

TapImmune Releases Positive Interim Data On Phase I Clinical Trial Of Folate Receptor Alpha Antigens In Ovarian And Breast Cancer

TapImmune Releases Positive Interim Data On Phase I Clinical Trial Of Folate Receptor Alpha Antigens In Ovarian And Breast Cancer

TapImmune Inc. (OTCQB:TPIV) is extremely pleased to report that analysis of the interim data from the first 13 patients in a Phase I clinical trial show that each of the patients treated have raised specific T-cell ...

TapImmune, Inc. Announces $2 Million Registered Direct Offering

TapImmune, Inc. Announces $2 Million Registered Direct Offering

TapImmune, Inc. (the “Company”), (OTCQB:TPIV), today announced that it has entered into a definitive agreement with an institutional investor for a registered direct placement of $2,000,000 of common stock at a ...

TapImmune's New Clinical Trial In Advanced Stage Ovarian Cancer Expands The Use Of Folate Receptor Alpha Peptide Antigens

TapImmune's New Clinical Trial In Advanced Stage Ovarian Cancer Expands The Use Of Folate Receptor Alpha Peptide Antigens

TapImmune Inc. (OTCQB:TPIV) is pleased to announce that a new grant funded Phase I clinical study on the safety and Immunogenicity of folate receptor alpha peptide vaccine in patients with advanced stage epithelial...

TapImmune Appoints Leading Immunotherapy Researcher To Chair Scientific Advisory Board

TapImmune Appoints Leading Immunotherapy Researcher To Chair Scientific Advisory Board

TapImmune Inc. (OTCQB:TPIV) is pleased to announce that Dr.

TapImmune Inc. Is Pleased To Provide An Update On Corporate Events And Milestones For 2014

TapImmune Inc. Is Pleased To Provide An Update On Corporate Events And Milestones For 2014

TapImmune Inc. (OTCQB:TPIV), A clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease is pleased to update ...

TapImmune Closes $1.16 Million Funding

Company Retires Notes and 11.2 Million Warrants